AKT 10081

Drug Profile

AKT 10081

Alternative Names: AKT-10081

Latest Information Update: 18 Dec 2015

Price : $50

At a glance

  • Originator Akthelia Pharmaceuticals
  • Class Antidiarrhoeals; Peptide antibiotics; Peptides
  • Mechanism of Action Peptide modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Clostridium infections; Diarrhoea

Most Recent Events

  • 18 Dec 2015 AKT 10081 is available for licensing as of 18 Dec 2015. http://www.akthelia.is/
  • 17 Dec 2015 Phase-II clinical trials in Clostridium infections in Iceland (unspecified route) prior to December 2015
  • 17 Dec 2015 Phase-II clinical trials in Diarrhoea in Iceland (unspecified route) prior to December 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top